ASX
LCT 0.052   Last updated 8.14 pm
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheets provide a summary of our current business and research pipeline.

Living Cell Technologies (LCT)

Living Cell Technologies is an Australasian biotechnology company and world leader in developing cell therapies to treat diseases with high unmet clinical need.

 

Our treatments are based on cell encapsulation and implantation for human therapeutics. We currently have two products in clinical development: DIABECELL® for the treatment of type 1 diabetes which is in late stage clinical trials and NTCELL® which is in Phase I clinical trials in New Zealand for the treatment of Parkinson’s disease.

 

Living Cell Technologies leads the world in cell transplant research. Our product pipeline consists of cell therapies developed from cells sourced from a unique herd of disease-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands.

 

Our unique proprietary technology, IMMUPEL™, coats cells with protective capsules that prevent attacks by the patient’s immune system. This allows the use of cell therapies without the need for co-treatment with drugs that suppress the immune system, which often have negative side effects.

— 18 August 2014

Successful second implant of NTCELL for Parkinson's disease

Living Cell Technologies Limited today announced that a second patient has been successfully implanted at Auckland City Hospital in the clinical trial of the regenerative cell therapy NTCELL® for Parkinson’s disease.

Read More Read Less

— 15 August 2014

Preliminary Final Report 30 June 2014

Living Cell Technologies Limited today announced the Preliminary Final Report (Appendix 4E) on the results for the year ended 30 June 2014.

Read More Read Less
Load More

— 8 May 2014

Please refer to our news releases

Load More
— 8 May 2014

There are no forthcoming events at present.

Load More
Announcements

— 18 August 2014

Successful second implant of NTCELL for Parkinson's disease

Living Cell Technologies Limited today announced that a second patient has been successfully implanted at Auckland City Hospital in the clinical trial of the regenerative cell therapy NTCELL® for Parkinson’s disease.

Read More Read Less

— 15 August 2014

Preliminary Final Report 30 June 2014

Living Cell Technologies Limited today announced the Preliminary Final Report (Appendix 4E) on the results for the year ended 30 June 2014.

Read More Read Less
Load More
LCT in the News

— 8 May 2014

Please refer to our news releases

Load More
Events
— 8 May 2014

There are no forthcoming events at present.

Load More
© 2014 Living Cell Technologies Limited.
site by { brownpaperbag }